GHK-Cu solution may show a faint blue or green tint after reconstitution
a)(semaglutide)b)0.1%(w/w)c)6.4 mg/mld)e)60%f)pHHClNaOHpH6-107-8In some embodiments, the pharmaceutical formulation consists of or consists essentially of: a) semaglutide, optionally b) not more than 0.1% (w/w) phenol, c) more than 6.4 mg/ml sodium chloride, d) buffer, e) at least 60% water, optionally f) one or more pH adjustment reagents, such as HCl, NaOH or acetate, and the formulation optionally has pH Value 6-10, for example 7-8
However, our findings showing mostly analogous serum IL-1 and TNF- levels between ALS patients and controls supported the recent study of Furukawa T et al
Nevertheless, the heterogeneity of study designs, sample sizes, and a paucity of long-term safety data highlight the need for standardized protocols and further high-quality trials
It is typically combined with other therapies, such as EBOO, IV protocols, and targeted antimicrobial support, as part of a comprehensive treatment plan